Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $231

Benzinga · 1d ago
Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $222 to $231.